ASLAN Pharmaceuticals Limited
ASLN · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.03 | -0.30 | 0.12 |
| FCF Yield | -269.75% | -76.53% | -23.33% | -10.70% |
| EV / EBITDA | -0.58 | -0.65 | -2.95 | -9.44 |
| Quality | ||||
| ROIC | -324.03% | -104.33% | -42.09% | -188.73% |
| Gross Margin | 97.10% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.05 | 0.75 | 1.08 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | – |
| Free Cash Flow Growth | -20.66% | -12.89% | -126.09% | 41.65% |
| Safety | ||||
| Net Debt / EBITDA | -0.14 | 0.41 | 2.01 | -0.32 |
| Interest Coverage | -10.11 | -13.03 | -18.19 | -13.21 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -8,288.35 | -14,065.74 | -4,030.94 | -2,843.38 |